FDA Accepts sBLA, Grants Priority Review to Liso-Cel in Pretreated MZL
Results from the marginal zone lymphoma cohort of the TRANSCEND FL trial showed liso-cel elicited an ORR of 95.5% and a CR rate of 62.1%.
Previous Post
FDA Upgrades Recall on More Than 33,000 Bottles of Blood Pressure Drugs Nationwide
Next Post
Creatine May Enhance Neuroprotection Through Energy Pathways
📢
Advertisement
300x250 Banner
Recent Content
COPD Biologics: Early Treatment Insights
Pulmonology • 2 hours ago
Antihypertensive Medication Guidelines
Cardiology • 4 hours ago
Juvenile Arthritis Care Transition
Rheumatology • 6 hours ago